How has the entecavir market evolved, and where is it heading next?
The entecavir market size has grown strongly in recent years. It will grow from $0.71 billion in 2024 to $0.75 billion in 2025 at a compound annual growth rate (CAGR) of 4.9%. The growth in the historic period can be attributed to rise in incidence of hepatitis B, rise in awareness on liver related diseases, increase in focus on personalized medicine, growth in online shopping for medications, and increase in availability of entecavir.
The entecavir market size is expected to see strong growth in the next few years. It will grow to $0.89 billion in 2029 at a compound annual growth rate (CAGR) of 4.5%. The growth in the forecast period can be attributed to rising initiatives to combat liver diseases, increasing adoption of digital healthcare solutions, increasing healthcare infrastructure, rising health insurance coverage, and increasing demand for anti viral medications. Major trends in the forecast period include integration of genetic testing, integration of advanced diagnostic tools, advancements in personalized medicine, adoption of combination therapies, and advancements in monitoring techniques.
Get Your Free Sample of The Global Entecavir Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21183&type=smp
What are the key drivers behind the rapid expansion of the entecavir market?
The increasing prevalence of liver diseases is expected to propel the growth of the entecavir market going forward. Liver diseases refer to a range of conditions that impair liver function, including infections, genetic disorders, and lifestyle-related damage such as fatty liver, hepatitis, cirrhosis, and liver cancer. The increase in liver diseases is driven by factors such as viral hepatitis (HBV and HCV), rising obesity rates, alcohol abuse, and metabolic disorders. Entecavir, an antiviral medication, supports liver disease patients by effectively inhibiting the replication of the hepatitis B virus, thereby reducing viral load, improving liver function, and lowering the risk of cirrhosis and liver cancer, which ultimately helps in managing chronic hepatitis B infections and preventing further liver damage. For instance, in June 2024, according to the Cancer Council Victoria, a US-based non-profit organization, 617 Victorians were diagnosed with liver cancer in 2022, of which 419 males and 198 females, representing 67.9% and 32.1% of the total Victorian liver cancer diagnoses. Furthermore, in 2025, according to the Liver Foundation, an Australia-based non-profit organization, every year, around 3,000 people are diagnosed with Hepatocellular carcinoma (HCC). Therefore, the increasing incidence of liver diseases is driving the growth of the entecavir market.
Rising Hepatitis B Prevalence Driving The Growth Of The Market
The increasing prevalence of hepatitis B is expected to propel the growth of the entecavir market going forward. Hepatitis B refers to a viral infection that affects the liver, causing jaundice, fatigue, and abdominal pain, and can lead to chronic liver disease or liver cancer if left untreated. The increase in hepatitis B cases is attributed to factors such as unprotected sexual contact, sharing of needles, mother-to-child transmission during childbirth, and insufficient vaccination coverage in certain regions. Entecavir helps treat hepatitis B by inhibiting the replication of the hepatitis B virus (HBV) DNA, reducing viral load and preventing liver damage. For instance, in January 2025, according to the UK Health Security Agency, a UK-based government agency, reported that in 2022, about 270,000 people, or 0.6% of the population, were living with hepatitis B. This number is expected to double by 2030 among diagnosed cases. Therefore, the increasing prevalence of hepatitis B is driving the growth of the entecavir market.
What is the segmentation for the entecavir market?
The entecavir market covered in this report is segmented –
1) By Product Type: Tablets, Oral Solution
2) By Application: Hepatitis B Treatment, Liver Transplantation, Other Applications
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Tablets: Standard Dose Tablets, High Dose Tablets
2) By Oral Solution: Ready-to-Use Liquid Solution, Powder For Oral Solution
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/entecavir-global-market-report
Who are the most influential companies in the entecavir market?
Major companies operating in the entecavir market are Bristol-Myers Squibb Company, GSK plc, Teva Pharmaceutical Industries Ltd., Qingfeng Pharmaceutical Group, Aurobindo Pharma Ltd., ScinoPharm Taiwan Ltd., Dr. Reddy’s Laboratories Ltd., Cipla Inc., Zhejiang Huahai Pharmaceuticals Co. Ltd., Qianjin Group, Genix Pharma Ltd., Dawnrays Pharmaceutical Holidings Ltd., Zhejiang Ausun Pharmaceutical Co. Ltd., Hunan Warrant Chiral Pharmaceutical Co. Ltd., Camber Pharmaceuticals Inc., Century Pharmaceuticals Ltd., Aligos Therapeutics Inc. , HRV Global Life Sceince, Solco Healthcare LLC, Accela ChemBio Inc.
What are the most influential trends expected to drive the entecavir market forward?
Major companies operating in the entecavir market are developing innovative drugs through clinical trial to enhance the efficacy and treatment outcomes for patients with chronic hepatitis B, potentially reducing resistance and improving long-term viral suppression. Clinical trials are research studies conducted to evaluate the safety, efficacy, and potential side effects of new treatments, drugs, or therapies in human participants. For instance, in October 2024, Aligos Therapeutics Inc., a US-based biotechnology company is undergoing phase 2 clinical trial for ALG-000184 for the treatment of hepatitis B. ALG-000184 is a type of therapy known as a capsid assembly modulator, which works by disrupting the formation of the capsid, the protective shell surrounding a virus’s genetic material. The fourth phase of the study is currently assessing the long-term effects of ALG-000184 (300 mg), either as a standalone treatment or in combination with the approved antiviral entecavir (sold as Baraclude, with generics available), in patients with chronic hepatitis B. The combination of ALG-000184 and entecavir resulted in more significant reductions in viral load compared to entecavir alone, with ALG-000184 demonstrating similar effectiveness regardless of whether it was used alongside entecavir. The virus remained consistently suppressed throughout the study, both in patients who were HBeAg-positive and HBeAg-negative.
What are the major regional insights for the entecavir market, and which region holds the top position?
Asia-Pacific was the largest region in the entecavir market in 2024. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the entecavir market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Entecavir Market Report 2025 Offer?
The entecavir market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Entecavir is an antiviral drug prescribed for managing chronic hepatitis B. It functions by blocking the replication of the hepatitis B virus, thereby lowering the viral load. This helps reduce the chances of severe liver damage and complications such as cirrhosis or liver cancer.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21183
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
